ARS Pharmaceuticals (SPRY) Other Operating Expenses (2022 - 2026)

ARS Pharmaceuticals has disclosed Other Operating Expenses across 5 years of filings, most recently posting $6.3 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $6.3 million, up 474.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.6 million (up 1136.84% YoY), and the FY2025 annual result was $20.4 million, up 1990.38% from the prior year.
• Other Operating Expenses came in at $6.3 million for Q1 2026 at ARS Pharmaceuticals, up from $6.2 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $17.9 million in Q4 2022 to a low of $112000.0 in Q3 2024.
• The 5-year median for Other Operating Expenses is $5.6 million (2025), against an average of $5.9 million.
• Across the five-year window, Other Operating Expenses soared 7213.39% in 2025 and jumped 474.59% in 2026, its largest moves.
• ARS Pharmaceuticals' Other Operating Expenses stood at $17.9 million in 2022, then retreated by 26.49% to $13.1 million in 2023, then plunged by 93.41% to $865000.0 in 2024, then jumped by 611.45% to $6.2 million in 2025, then climbed by 2.14% to $6.3 million in 2026.
• The last three Other Operating Expenses figures came in at $6.3 million (Q1 2026), $6.2 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.